BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19000250)

  • 1. Phase I dose escalation of single-agent vinblastine in dogs.
    Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
    J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of vinblastine for treatment of canine mast cell tumors.
    Rassnick KM; Bailey DB; Flory AB; Balkman CE; Kiselow MA; Intile JL; Autio K
    J Vet Intern Med; 2008; 22(6):1390-6. PubMed ID: 19000249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
    Lenz JA; Robat CS; Stein TJ
    J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma.
    Frimberger AE; Moore AS; Rassnick KM; Cotter SM; O'Sullivan JL; Quesenberry PJ
    J Vet Intern Med; 2006; 20(2):355-64. PubMed ID: 16594594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of vinorelbine in tumor-bearing cats.
    Pierro JA; Mallett CL; Saba CF
    J Vet Intern Med; 2013; 27(4):943-8. PubMed ID: 23662626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
    Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
    J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
    Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
    J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
    Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
    J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia.
    Poirier VJ; Burgess KE; Adams WM; Vail DM
    J Vet Intern Med; 2004; 18(4):536-9. PubMed ID: 15320594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
    Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
    J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma.
    Harding K; Bergman N; Smith A; Lindley S; Szivek A; Milner R; Brawner W; Lejeune A
    Vet Comp Oncol; 2018 Dec; 16(4):636-641. PubMed ID: 30117260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
    Thamm DH; Turek MM; Vail DM
    J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
    Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
    J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
    Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
    Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage escalation of intravenous cyclophosphamide in cats with cancer.
    Moore AS; Frimberger AE; Chan CM
    Vet J; 2018 Dec; 242():39-43. PubMed ID: 30503542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
    Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
    J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
    Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
    J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
    Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
    J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.